{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969026",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969026_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"acarbose\" outputclass=\"int-drug\">acarbose</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  acarbose  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acarbose</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969027",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969027_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"alogliptin\" outputclass=\"int-drug\">alogliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  alogliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alogliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969028",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969028_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"amiodarone\" outputclass=\"int-drug\">Amiodarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Amiodarone   is predicted to   increase   the exposure to   gliclazide .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiodarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969029",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969029_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"bezafibrate\" outputclass=\"int-drug\">Bezafibrate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypoglycaemia when given with</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Bezafibrate   is predicted to   increase   the risk of hypoglycaemia when given with   gliclazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bezafibrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969030",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969030_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"canagliflozin\" outputclass=\"int-drug\">canagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  canagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969031",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969031_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chloramphenicol\" outputclass=\"int-drug\">Chloramphenicol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chloramphenicol   is predicted to   increase   the exposure to   gliclazide .  Manufacturer advises monitor blood glucose .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chloramphenicol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969032",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969032_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ciprofibrate\" outputclass=\"int-drug\">Ciprofibrate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypoglycaemia when given with</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ciprofibrate   is predicted to   increase   the risk of hypoglycaemia when given with   gliclazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciprofibrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969033",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969033_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Clarithromycin   is predicted to   slightly   increase   the exposure to   gliclazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969034",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969034_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"dapagliflozin\" outputclass=\"int-drug\">dapagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  dapagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969035",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969035_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"dulaglutide\" outputclass=\"int-drug\">dulaglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  dulaglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dulaglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969036",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969036_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"empagliflozin\" outputclass=\"int-drug\">empagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  empagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Empagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969037",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969037_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"ertugliflozin\" outputclass=\"int-drug\">ertugliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  ertugliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ertugliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969038",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969038_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"exenatide\" outputclass=\"int-drug\">exenatide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  exenatide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Exenatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969039",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969039_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fenfluramine\" outputclass=\"int-drug\">Fenfluramine</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">blood glucose concentrations when given with</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fenfluramine   might   decrease   blood glucose concentrations when given with   gliclazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fenfluramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969040",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969040_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fenofibrate\" outputclass=\"int-drug\">Fenofibrate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypoglycaemia when given with</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fenofibrate   is predicted to   increase   the risk of hypoglycaemia when given with   gliclazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fenofibrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969041",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969041_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">Fluconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluconazole   is predicted to   increase   the exposure to   gliclazide .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969042",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969042_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"gemfibrozil\" outputclass=\"int-drug\">Gemfibrozil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypoglycaemia when given with</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Gemfibrozil   is predicted to   increase   the risk of hypoglycaemia when given with   gliclazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemfibrozil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969043",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969043_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"insulin\" outputclass=\"int-drug\">insulin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  insulin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Insulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969044",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969044_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"linagliptin\" outputclass=\"int-drug\">linagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  linagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969045",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969045_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"liraglutide\" outputclass=\"int-drug\">liraglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  liraglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Liraglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969046",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969046_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"lixisenatide\" outputclass=\"int-drug\">lixisenatide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  lixisenatide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lixisenatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969047",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969047_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"metformin\" outputclass=\"int-drug\">metformin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  metformin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metformin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969048",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969048_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metreleptin\" outputclass=\"int-drug\">Metreleptin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypoglycaemia when given with</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Metreleptin   is predicted to   increase   the risk of hypoglycaemia when given with   gliclazide .  Manufacturer advises monitor blood glucose and adjust dose .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metreleptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969049",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969049_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"miconazole\" outputclass=\"int-drug\">Miconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Miconazole   is predicted to   increase   the exposure to   gliclazide .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Miconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969050",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969050_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"pioglitazone\" outputclass=\"int-drug\">pioglitazone</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  pioglitazone  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pioglitazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969051",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969051_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"repaglinide\" outputclass=\"int-drug\">repaglinide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  repaglinide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Repaglinide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969052",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969052_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   gliclazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969053",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969053_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"saxagliptin\" outputclass=\"int-drug\">saxagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  saxagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saxagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969054",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969054_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"semaglutide\" outputclass=\"int-drug\">semaglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  semaglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Semaglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969055",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969055_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"sitagliptin\" outputclass=\"int-drug\">sitagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  sitagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sitagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969056",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969056_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sulfadiazine\" outputclass=\"int-drug\">Sulfadiazine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sulfadiazine   is predicted to   increase   the exposure to   gliclazide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfadiazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969057",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969057_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sulfadoxine\" outputclass=\"int-drug\">Sulfadoxine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sulfadoxine   is predicted to   increase   the exposure to   gliclazide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfadoxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969058",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969058_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sulfamethoxazole\" outputclass=\"int-drug\">Sulfamethoxazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sulfamethoxazole   is predicted to   increase   the exposure to   gliclazide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfamethoxazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969059",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969059_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph> and <ph otherprops=\"vildagliptin\" outputclass=\"int-drug\">vildagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  gliclazide  and  vildagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vildagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969060",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2#bnf_i1643857969060_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">Voriconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"gliclazide\" outputclass=\"int-heading-drug\">gliclazide</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Voriconazole   is predicted to   increase   the concentration of   gliclazide .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				}
			],
			"hasSearchLabel": " Gliclazide  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/gliclazide-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Gliclazide </title>"
			},
			"rdfs:label": "gliclazide"
		}
	]
}